pharma · Agitation · Agitation,Psychomotor · BTAI
BioXcel Therapeutics
BioXcel Therapeutics patent portfolio — 18 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US
- Founded
- 2017
- Employees
- 56
- Programs
- 17
- Drugs
- 9
- Patents
- 18
BioXcel Therapeutics patents
18 pharmaceutical patents indexed for BioXcel Therapeutics. 0 expire within 24 months.
BioXcel Therapeutics has 18 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12364683
Non-sedating dexmedetomidine treatment regimens
granted -
US 12138247
Non-sedating dexmedetomidine treatment regimens
granted -
US 12109196
Non-sedating dexmedetomidine treatment regimens
granted -
US 12090140
Non-sedating dexmedetomidine treatment regimens
granted -
US 11998528
Non-sedating dexmedetomidine treatment regimens
granted -
US 11998529
Non-sedating dexmedetomidine treatment regimens
granted -
US 11931340
Use of sublingual dexmedetomidine for the treatment of agitation
granted -
US 11890272
Non-sedating dexmedetomidine treatment regimens
granted -
US 11839604
Use of sublingual dexmedetomidine for the treatment of agitation
granted -
US 11806429
Film formulations containing dexmedetomidine and methods of producing them
granted -
US 11806334
Non-sedating dexmedetomidine treatment regimens
granted -
US 11786508
Use of sublingual dexmedetomidine for the treatment of agitation
granted -
US 11559484
Film formulations containing dexmedetomidine and methods of producing them
granted -
US 11517524
Film formulations containing dexmedetomidine and methods of producing them
granted -
US 11497711
Film formulations containing dexmedetomidine and methods of producing them
granted -
US 11478422
Film formulations containing dexmedetomidine and methods of producing them
granted -
US 10792246
Film formulations containing dexmedetomidine and methods of producing them
granted -
US 10610563
Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
granted
Frequently asked questions
How many patents does BioXcel Therapeutics have?
18 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do BioXcel Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.